The BCL2L12 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, designed for functional disruption of the BCL2L12 gene. This heterogeneous pool of edited cells enables loss-of-function studies without the clonal selection bottlenecks, preserving phenotypic diversity while abolishing BCL2L12-mediated pro-apoptotic signaling. The product is supplied as a polyclonal population, facilitating robust experimental replicates in apoptosis and cancer biology research.
HT29 is a widely employed epithelial cell line isolated from a primary colorectal adenocarcinoma, characterized by its adherent morphology and multiple oncogenic lesions, including mutations in APC, TP53, and components of the PI3K pathway. This genetic background makes HT29 an invaluable model for dissecting intestinal epithelial homeostasis and the molecular determinants of colorectal cancer progression, particularly in the context of defective p53-dependent apoptosis and chemoresistance.
BCL2L12 encodes a pro-apoptotic member of the BCL2 protein family that functions downstream of p53 and cellular stress signals. Upon activation, BCL2L12 binds and neutralizes anti-apoptotic factors such as BCL2, BCL-XL, and MCL1, thereby facilitating the oligomerization of BAX and BAK at the mitochondrial outer membrane. This event triggers cytochrome c release into the cytosol, leading to apoptosome assembly and subsequent activation of caspase-9 and the effector caspase-3, culminating in apoptotic cell death. The protein thus operates as a critical amplifier of the intrinsic apoptotic pathway, integrating upstream DNA damage and oncogenic signals.
In the HT-29 colorectal cancer context, knockout of BCL2L12 attenuates the intrinsic apoptotic response, mimicking the apoptosis resistance frequently observed in advanced colorectal tumors. The loss-of-function model allows researchers to interrogate how p53-mediated cell death is subverted and to dissect the contribution of BCL2 family interactions to survival signaling. This cellular system is particularly suited for evaluating the mechanistic basis of resistance to conventional chemotherapeutics such as 5-fluorouracil and oxaliplatin, which rely on intact apoptotic machinery for efficacy.
Applications include detailed characterization of apoptosis signaling networks via Western blotting and RT-qPCR for pathway component expression, assessment of mitochondrial outer membrane permeabilization through cytochrome c immunofluorescence, and quantitative measurement of caspase-3/7 activity. The polyclonal knockout cells also support co-immunoprecipitation studies to map altered protein?Cprotein interactions within the BCL2 family and Annexin V flow cytometry to quantify apoptotic rates in response to genotoxic stress. Chemosensitivity screens using standard-of-care colorectal cancer agents can be performed to identify response modifiers. For further details and custom inquiry, please contact Ascent Research.
